UOC
BPMC

UBS O'Connor’s Blueprint Medicines BPMC Stock Holding History

UBS O'Connor’s Portfolio BPMC Stock Details BPMC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-1,713,587
Closed -$220M – 309
2025
Q2 		$220M Buy
1,713,587
+1,698,722
+11,428% +$176M 6.11% 4
2025
Q1 		$1.32M Sell
14,865
-5,268
-26% -$514K 0.03% 162
2024
Q4 		$1.76M Sell
20,133
-2,120
-10% -$194K 0.04% 170
2024
Q3 		$2.06M Buy
22,253
+5,910
+36% +$587K 0.05% 167
2024
Q2 		$1.76M Sell
16,343
-1,657
-9% -$166K 0.05% 212
2024
Q1 		$1.71M Buy
18,000
+9,000
+100% +$772K 0.05% 208
2023
Q4 		$830K Sell
9,000
-39,984
-82% -$2.59M 0.03% 295
2023
Q3 		$2.46M Buy
48,984
+1,200
+3% +$64.1K 0.04% 207
2023
Q2 		$3.02M Sell
47,784
-1,449
-3% -$78.8K 0.06% 192
2023
Q1 		$2.21M Buy
+49,233
New +$2.22M 0.05% 299
2022
Q3 		– Sell
-20,390
Closed -$1.03M – 966
2022
Q2 		$1.03M Buy
+20,390
New +$1.19M 0.01% 756

Other funds holding BPMC

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return
VanEck Associates
VanEck Associates New York $133B AUM 72.99% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $4.82B AUM 20.19% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

UBS O'Connor's BPMC Position: Q3 2025 in Review

UBS O'Connor sold out of Blueprint Medicines (BPMC) in Q3 2025, closing a stake of 1,713,587 shares — an estimated $220M sold.

UBS O'Connor first reported a position in BPMC in Q2 2022 and held it in 11 quarters. The position peaked at $220M in Q2 2025. 5 funds tracked by Wall St. Rank hold BPMC as of Q3 2025.

  • UBS O'Connor reported no remaining Blueprint Medicines position as of Q3 2025 after selling out during the quarter.
  • UBS O'Connor sold 1,713,587 Blueprint Medicines shares in Q3 2025, an estimated $220M.
  • UBS O'Connor first reported a position in Blueprint Medicines in Q2 2022 and held it in 11 quarters.
  • UBS O'Connor's Blueprint Medicines position peaked at $220M in Q2 2025.
  • 5 funds tracked by Wall St. Rank held Blueprint Medicines as of Q3 2025.

Based on UBS O'Connor's 13F filing for Q3 2025, filed 14 Nov 2025.